DrugPatentWatch Database Preview
Novo Company Profile
What is the competitive landscape for NOVO, and when can generic versions of NOVO drugs launch?
NOVO has forty-five approved drugs.
There are fifty-seven US patents protecting NOVO drugs.
There are five hundred and eighty-three patent family members on NOVO drugs in thirty-nine countries and one hundred and sixty-four supplementary protection certificates in eighteen countries.
Summary for Novo
| International Patents: | 583 |
| US Patents: | 57 |
| Tradenames: | 55 |
| Ingredients: | 37 |
| NDAs: | 45 |
| Patent Litigation for Novo: | See patent lawsuits for Novo |
Drugs and US Patents for Novo
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | NORDITROPIN FLEXPRO | somatropin | INJECTABLE;INJECTION | 021148-008 | Mar 1, 2010 | BX | RX | No | No | 9,108,002 | Start Trial | Y | Start Trial | ||
| Novo Nordisk Inc | NORDITROPIN FLEXPRO | somatropin | INJECTABLE;INJECTION | 021148-010 | Mar 1, 2010 | RX | No | No | 10,357,616 | Start Trial | Y | Start Trial | |||
| Novo Nordisk Inc | NOVOLOG FLEXTOUCH | insulin aspart recombinant | INJECTABLE;SUBCUTANEOUS | 020986-005 | Oct 31, 2013 | DISCN | Yes | No | 8,579,869 | Start Trial | Y | Start Trial | |||
| Novo | TRESIBA | insulin degludec | SOLUTION;SUBCUTANEOUS | 203314-001 | Sep 25, 2015 | RX | Yes | No | 10,357,616 | Start Trial | Y | Start Trial | |||
| Novo Nordisk Inc | NOVOLOG FLEXTOUCH | insulin aspart recombinant | INJECTABLE;SUBCUTANEOUS | 020986-005 | Oct 31, 2013 | DISCN | Yes | No | 9,687,611 | Start Trial | Y | Start Trial | |||
| Novo Nordisk Inc | NORDITROPIN FLEXPRO | somatropin | INJECTABLE;INJECTION | 021148-010 | Mar 1, 2010 | RX | No | No | 9,687,611 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Novo
Paragraph IV (Patent) Challenges for NOVO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 18 mg/3 mL prefilled syringe | ➤ Subscribe | 2016-12-12 |
| ➤ Subscribe | Vaginal Tablets | 10 mcg | ➤ Subscribe | 2013-01-02 |
| ➤ Subscribe | Tablets | 1 mg/500 mg and 2 mg/500 mg | ➤ Subscribe | 2009-04-09 |
International Patents for Novo Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5757530 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2007093820 | Start Trial |
| Czech Republic | 9900629 | Start Trial |
| Japan | 2015517458 | Start Trial |
| Czech Republic | 20024095 | Start Trial |
| New Zealand | 273285 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Novo Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2209800 | C02209800/01 | Switzerland | Start Trial | PRODUCT NAME: INSULIN DEGLUDEC + LIRAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC 65041 12.09.2014 |
| 0705275 | SPC/GB00/027 | United Kingdom | Start Trial | PRODUCT NAME: INSULIN ASPART AND PROTAMINE (NOVOMIX 30); REGISTERED: CH 55414 01 20000623; CH 55415 02 20000623; CH 55416 02 20000623; UK EU/1/00/142/001-008 20000801 |
| 2107069 | 2013/034 | Ireland | Start Trial | PRODUCT NAME: INSULIN DEGLUDEC; NAT REGISTRATION NO/DATE: EU/1/12/807-001, 004, 005, 007-009, 012, 013 015 20130121 |
| 0334429 | 97C0002 | Belgium | Start Trial | PRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305 |
| 2340033 | 2017C/024 | Belgium | Start Trial | PRODUCT NAME: SNELWERKENDE INSULINE ASPART; AUTHORISATION NUMBER AND DATE: EU/1/16/1160 20170111 |
| 1506211 | C 2014 029 | Romania | Start Trial | PRODUCT NAME: COMBINATIE DE DAPAGLIFLOZIN SAU O SARE ACCEPTABILAFARMACEUTIC A ACESTUIA SI METFORMINA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTEIA; NATIONAL AUTHORISATION NUMBER: EU/1/13/900; DATE OF NATIONAL AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/900; DATE OF FIRST AUTHORISATION IN EEA: 20140116 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
